Glycosylation analysis studies of proteins, including assessment of glycosylation site, carbohydrate content and glycan structure in line with ICH guidelines
Glycosylation is a common post translational modification (PTM) and involves enzymatic addition of a carbohydrate (or glycan) to certain sites within a protein. Influenced by the cell line, as well as other environmental factors, changes in the N-glycosylation and O-glycosylation can potentially affect the bioactivity, safety and efficacy of the protein therapeutic.
Glycosylation is a non-heterogeneous process and as such can give rise to a wide range of different functional structures. The diversity of these protein glycoforms, as well as understanding the structure of glycans must be well understood in order to reduce risks associated with patient safety and loss of biological activity of the glycoprotein therapeutic.
Our protein characterisation scientists provide detailed glycosylation studies in accordance with relevant EMA, FDA and ICH guidelines. Our analytical programs are designed to support our clients throughout early stage development to product characterization and regulatory submission. Due to the complex nature of glycosylation structural characterisation, we deploy different approaches with each technique focused on accessing data on different aspects of the glycan or glycoprotein structure. The design of an analytical package is devised based on our expertise and experience.
Glycosylation analytical strategies are protein product specific, but typically, include determination of levels of neutral and amino monosaccharides as well as sialic acids, assessment of glycoform distribution and glycan structure elucidation. Multiple technologies are applied in these determinations including selective enzymatic cleavage, MALDI-TOF mass spectrometry and a range of chromatographic methods (HPLC, HILIC, IEX or CE-LIF).
Characterisation of glycoproteins
- Identification of glycosylation sites through peptide mapping
- Determination of glycosylation linkage (GC-MS)
- Determination of Gu or G0 values (CE or normal phase LC)
- Determination of glycan structure (enzyme array, MALDI-TOF)
- Total sugar (monosaccharides and oligosaccharide composition neutral and amino sugars)
- Determination of sialic acid residues, total and specific
We design programs to deliver the glycosylation information you need to meet the requirements of your development stage. Our extensive characterization programs can be provided to Good Laboratory Practice or Good Manufacturing Practice standard, as appropriate, supporting you every step of the development, regulatory submission, and ongoing manufacturing. Bringing quality and safety to life, Intertek offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards.
ICH Q6B Protein Analysis Services
COVID-19 VACCINE OR THERAPEUTIC TESTING & DEVELOPMENT SUPPORT
IMMEDIATE QUESTION? Ask our experts now
FACTSHEET: COVID-19 Vaccine or Therapeutic Testing & Development Outsourcing
ARTICLE: Repurposing Vaccines for Intranasal Development
WEBINAR: Quality Control Strategy for Vaccine Development
WEBINAR: Repurposing Drugs for Inhaled Delivery
eBOOK: Contingency Outsourcing Solutions
ARTICLES
New Approaches to Bioassay Design
Characterisation of Bispecifics
The Significance and Challenges of Inhaled and Nasal Biologics
Current Analytical Approaches to Biophysical Characterisation
Biosimilar Characterisation and Immunogenicity
WHITEPAPER DOWNLOADS
Liposome Physicochemical Property Analysis
Formulation of Biologics for Inhaled and Nasal Delivery
The Complexities of Antibody Drug Conjugate Characterization
BROCHURES
Download: Intertek Biopharmaceutical Services Brochure
Download: Intertek Pharmaceutical Services
Intertek Pharmaceutical Services Manchester
P.O. Box 42
Hexagon Tower
Blackley
Manchester, M9 8ZS
United Kingdom
For location use: M9 8GQ